SMAD2 and Insulin resistance: It has previously been demonstrated in animal models that the upregulation or administration of myostatin promotes insulin resistance, which may involve the repression of insulin-stimulated protein kinase B (Akt) phosphorylation by the activation of SMAD2/3 [73], which subsequently impairs the distal insulin signaling cascade [17, 18, 74].